DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Gemcitabine
Drug: 5-Fluorouracil
Procedure: Radiation Therapy

First Posted Date: 2005-11-10

Last Posted Date: 2016-12-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT00251355

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Taxotere, Cisplatin, and CPT-11 in Advanced Solid Tumor Malignancies

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: Taxotere
Drug: Cisplatin
Drug: CPT-11

First Posted Date: 2005-11-10

Last Posted Date: 2012-08-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 46

Registration Number: NCT00251407

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Multicenter Study of 9-Aminocamptothecin (9-AC) in Patients With Refractory Leukemia

Phase 1

Completed

Conditions: Acute Lymphocytic Leukemia
Leukemia, Myelocytic, Acute

First Posted Date: 2005-11-10

Last Posted Date: 2011-03-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 52

Registration Number: NCT00251368

Locations: 🇺🇸
Massachusetts General Hosptial, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Study of Dynavax's 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma

Phase 2

Completed

Conditions: Non-Hodgkin's Lymphoma

First Posted Date: 2005-11-10

Last Posted Date: 2010-01-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00251394

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia

Phase 2

Completed

Conditions: Waldenstrom's Macroglobulinemia

Interventions: Drug: Bortezomib
Drug: Dexamethasone
Drug: Rituximab

First Posted Date: 2005-11-09

Last Posted Date: 2016-04-08

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 23

Registration Number: NCT00250926

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer

Phase 2

Completed

Conditions: Fallopian Tube Cancer
Peritoneal Cancer
Ovarian Cancer

Interventions: Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2005-10-03

Last Posted Date: 2018-08-13

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 44

Registration Number: NCT00230542

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: 5-Fluorouracil (5-FU)
Drug: Capecitabine
Drug: Irinotecan
Drug: Cisplatin

First Posted Date: 2005-09-22

Last Posted Date: 2018-11-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 54

Registration Number: NCT00215501

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Vinorelbine in Unresectable or Metastatic Esophageal and Gastric Adenocarcinoma

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer
Stomach Cancer

First Posted Date: 2005-09-22

Last Posted Date: 2009-04-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 32

Registration Number: NCT00215462

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma

Early Phase 1

Completed

Conditions: Gastro-esophageal Junction Cancer
Stomach Cancer
Gastric Cancer

Interventions: Drug: Epirubicin
Drug: Cisplatin
Drug: 5-Fluorouracil (5-FU)
Procedure: Radiation

First Posted Date: 2005-09-22

Last Posted Date: 2014-07-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT00215514

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Computerized Assessment for Patients With Cancer

Phase 3

Completed

Conditions: Neoplasms

Interventions: Behavioral: ESRA-C

First Posted Date: 2005-09-19

Last Posted Date: 2015-05-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 1058

Registration Number: NCT00194493

Locations: 🇺🇸
University of Washington Medical Center, Seattle, Washington, United States
🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy